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Tobacco harm reduction in people with serious mental illnesses 
People with serious mental illnesses, such as schizo-
phrenia and other psychoses, are much more likely to 
smoke cigarettes (50%) than are those without (15·5%).1,2 
They also smoke more cigarettes per day and inhale more 
deeply than other smokers, achieving higher blood levels 
of nicotine than smokers without serious mental illnesses.1
These high smoking rates among people with serious 
mental illnesses increase their risk of developing cancer 
and may be particularly harmful because smoking 
ampliﬁ es the increased risk of coronary heart disease 
due to the obesogenic eﬀ ects of atypical antipsychotic 
medications. Substantial mental health beneﬁ ts can 
be gained from quitting smoking, such as reduced 
symptoms of depression and anxiety that are common in 
people with serious mental illnesses.3
The higher smoking prevalence in people with serious 
mental illnesses is the result of a higher rate of smoking 
uptake, often before diagnosis, combined with fewer 
and less successful quit attempts.2,4 A strong interest 
in smoking cessation in people with serious mental 
illnesses nonetheless exists for the same reasons as in 
other smokers—ie, to improve their health. An additional 
motivation to quit is the substantial ﬁ nancial cost of 
cigarette smoking for people who often have very low 
incomes, which are largely derived from social welfare. 
The adoption of smoke-free policies in many 
psychiatric units has provided an additional reason to 
quit because people with serious mental illnesses will 
often spend some time each year in hospitals. These 
hospitalisations represent a major opportunity for 
interventions to encourage smoking cessation, which is 
often not taken up.5,6
An urgent need to provide eﬀ ective smoking cessation 
assistance to smokers with serious mental illnesses 
exists.1,6,7 Mental health service providers should ask their 
patients about their smoking and, if they smoke, either 
provide eﬀ ective smoking cessation assistance or refer their 
patients to services that can provide it. Cessation assistance 
should include psychosocial and pharmacological support, 
such as the giving of nicotine replacement therapy (eg, 
patches or gum), bupropion, or varenicline. 
Nicotine replacement therapy products and bupropion 
increase smoking abstinence in people with schizophrenia, 
but whether they are as eﬀ ective as in other smokers is 
not known because the longer-term outcomes of quit 
attempts have not been investigated in this population.8 
The authors of a review of seven randomised controlled 
trials of smoking cessation interventions in people with 
serious mental illnesses concluded that pharmaceutical 
and behavioural treatments seemed to be roughly 
equally eﬀ ective in smokers with and without serious 
mental illnesses.9 However, these results might not be 
generalisable to everyone with serious mental illnesses 
because participants in these trials could have better 
psychosocial functioning than non-participants.
Advice on smoking to people with serious mental 
illnesses should also include harm reduction advice—ie, 
advice to switch to alternative methods of nicotine delivery. 
Such advice is especially relevant for people with serious 
mental illnesses who do not currently want to quit 
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smoking or have experienced great diﬃ  culty in quitting, as 
shown by their failure to quit with good pharmacological 
and psychosocial support.7
Some people with serious mental illnesses ﬁ nd quitting 
much more diﬃ  cult than in other smokers because of 
socioeconomic disadvantage, cognitive impairment, or 
an absence of social support for abstinence from family 
and peers.4 In some people with schizophrenia, nicotine 
use might be a form of self-medication used to attenuate 
the negative symptoms of their disorder, improve their 
cognitive performance, or reduce the severity of the side 
eﬀ ects of their antipsychotic medication.10
In view of the serious harms from heavy smoking and 
the diﬃ  culty in cessation, a strong ethical case exists for 
the provision of harm reduction advice as one of the 
options oﬀ ered to smokers with serious mental illnesses. 
Such advice, if followed, will reduce the substantial harms 
that these people will be aﬀ ected by if they continue to 
smoke cigarettes heavily.11 Harm reduction products that 
can be suggested are shown in the panel, ordered by 
probable potential for reducing tobacco-related harm.14
Limited research exists on the success of harm 
reduction approaches to smoking in people with serious 
mental illnesses. A promising approach would be to trial 
e-cigarettes and other nicotine products for cessation 
and long-term maintenance in people with serious 
mental illnesses. Some small studies suggest that there 
is patient interest in using e-cigarettes.15 If this form of 
harm reduction proved eﬀ ective in such trials, we would 
need to make harm reduction products cheaper and 
easier to obtain for people with serious mental illnesses 
than cigarettes are now. This aim could be achieved most 
simply if governments decided to tax less harmful forms 
of nicotine, including e-cigarettes, sprays, patches, and 
lozenges, at a substantially lower rate than cigarettes to 
encourage their uptake by smokers. 
If more restrictive policies towards alternative forms 
of nicotine delivery are adopted, then other approaches 
might be necessary. Public subsidies could be provided 
for the forms of nicotine approved by medicines 
regulatory authorities, similar to the present National 
Institute for Health and Care Excellence harm reduction 
guidance for smokers with serious mental illnesses.7
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Panel: Tobacco harm reduction options
Pharmaceutical nicotine
Gum, patches, inhalers, and sprays 
• Safe, eﬀ ective, and cost eﬀ ective 
• Minimal risk of misuse
• Can be used as a long-term alternative (but few do because 
nicotine replacement therapy is designed to be less 
rewarding than smoking12)
Smokeless tobacco products
Low in nitrosamines, such as Swedish snus13 
• Eﬀ ective alternative to smoking in men
• Restricted success of this approach in countries such as 
Sweden and Norway 
• Bans on sales preclude their use in the European Union, 
Australia, and New Zealand
• Available in the USA and Canada
Electronic or e-cigarettes
Deliver nicotine as a vapour by heating a solution of nicotine and 
propylene glycol or vegetable glycerine, instead of burning tobacco
• Usually marketed as alternatives to cigarettes, rather than 
cessation aids
• Yet to be assessed in controlled trials as cessation aids 
• Appear to be promising as harm reduction products in 
observational studies14
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The 2013 WHO guidelines1 for the care of adolescents 
living with HIV/AIDS argue for the active engagement 
of HIV-positive adolescents themselves in the delivery 
of care for this population. However, these guidelines 
give few examples of how this engagement has been 
achieved in diﬀ erent contexts and provide only few 
recommendations on best practices. We believe that 
adolescents living with HIV can be important in the 
delivery of mental health services for their peers through 
a task-shifting approach, in which these adolescents are 
trained in basic psychological therapies.
Improved access to antiretroviral therapy and slow 
disease progression have helped children who were 
perinatally infected with HIV to survive to become adoles-
cents. Therefore, the psychosocial wellbeing of these 
HIV-positive adolescents has become a major concern 
for health-care providers and policy makers.2,3 The high 
burden of poor mental health in adolescents with HIV 
is worsened by stigma, sexual abuse, and poverty, and 
puts this group at increased risk for poor adherence to 
antiretroviral therapy.2,4 Health-care staﬀ  shortages and 
other constraints make mental health care access for this 
population in sub-Saharan Africa inadequate.5
A notable absence of culturally adapted, context-
speciﬁ c recommendations for addressing the mental 
health needs of these adolescents worsens the situation. 
For example, age-appropriate interventions for the 
disclosure of HIV status to adolescents or for any other 
common mental disorders such as depression and anxiety 
are scarce. To create the most eﬀ ective interventions for 
adolescents with HIV, mental health investigators need 
to design rigorous studies to establish culturally relevant 
psychosocial interventions for adolescents living with 
HIV, which take into account the particular needs and 
preferences of this growing population. 
Regardless of the outcomes of future investigations in 
low-income countries, severe shortages in mental health 
workers remain a barrier to eﬀ ective interventions. For 
example, in Ghana, only 11 psychiatrists are available for 
a population of 25 million people.6 Pioneers in global 
mental health advocate for a task-shifting approach to 
tackle workforce deﬁ ciencies.7 This approach typically 
includes the training of lay community members in the 
delivery of basic psychosocial care such as cognitive 
behavioural therapy and problem-solving therapy. The 
task-shifting approach has proven eﬀ ective for adults 
in settings with high HIV prevalence,8 but this approach 
has not been tested in adolescents with HIV.
Throughout Africa, adolescent HIV-positive peer 
educators assist in the health care of adolescents with 
HIV both in a formal and an informal basis.5,9 During 
a qualitative study9 undertaken by investigators at 
the largest adolescent HIV clinic in Zimbabwe, a boy 
aged 18 years summarised the beneﬁ ts of peer-based 
psychosocial support:
“At home alone I start thinking about my mother 
passing away. Here, the others counselled me in the 
support group. It helps calm my thoughts and removes 
bad thoughts. Here, you cannot blame yourself or say 
that you are the only one”. 
Zvandiri, a community-based organisation in Zimbabwe, 
trains adolescents with HIV to help provide HIV testing, 
counselling, and training of their peers with HIV.10 The 
success of Zvandiri has led the Ministry of Health and 
Child Care in Zimbabwe to scale up the programme to 
the national level.1 
Guardians and health-care providers might argue that 
these adolescents are not mature enough to be given 
responsibility for the mental health care of their peers, 
or that their status as both patients and health-care 
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